Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence. (October 2016)

• Record Type: Journal Article
• Authors: Simonyi, Gábor; Ferenci, Tamás; Alföldi, Sándor; Farsang, Csaba
• Is Part Of: Journal of international medical research. Volume 44:Number 5(2016:Oct.)
• Page Start: 1087
• Page End: 1091
• Publication Date: 2016-10
• Subjects: Adherence -- antihypertensive therapy -- ramipril + amlodipine fixed-dose combination -- ramipril +hydrochlorothiazide fixed-dose combination; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060516645004
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: To compare 1-year treatment adherence of ramipril + amlodipine and ramipril +hydroclorothiazide fixed-dose combination therapies in patients with hypertension. Methods: Data were extracted from the database of the National Health Insurance Fund of Hungary. Treatment adherence was modelled using survival analysis. Results: At 2 months after initiation of treatment, 42% of patients using ramipril +hydrochlorothiazide ( n = 28, 800) had discontinued treatment, compared with 0% of patients using ramipril + amlodipine ( n = 10, 295). At 1 year, treatment adherence was 29% in the ramipril + hydrochlorothiazide group and 54% in the ramipril + amlodipine group. The hazard ratio for discontinuing ramipril + hydrochlorothiazide vs ramipril + amlodipine was 2.318 (95% confidence intervals 2.246, 2.392). Conclusion: Ramipril + amlodipine had significantly higher 1-year treatment adherence than ramipril + hydrochlorothiazide in patients with hypertension.